Synovial Sarcoma
Conditions
Interventions
HANPs Group:Accepted HANPs implantation
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Patients, regardless of gender, aged between 18 and 75 years. 2.Pathologically confirmed diagnosis of either synovial sarcoma or chordoma. 3.The surgical approach for the tumor must be en bloc resection, achieving the required tumor-free margins (e.g., R0 or R1 resection). 4.ECOG Performance Status score of 0 or 1. 5.The patient voluntarily agrees to participate, provides written informed consent, and is willing to closely adhere to all study requirements, including attending all follow-up visits and assessments, and complying with the postoperative rehabilitation plan.
Exclusion criteria
Exclusion criteria: 1.Intraoperative tumor resection margins do not meet expectations, with R2 resection or tumor rupture causing contamination. 2.Severe cardiac, hepatic, renal, pulmonary, or cerebral dysfunction; severe calcium-phosphorus metabolic imbalance. 3.Pregnant or lactating women. 4.Systemic connective tissue disease. 5.Uncontrolled diabetes mellitus. 6.History of autoimmune diseases; HIV infection; history of immunosuppressive disorders or current use of immunosuppressive agents. 7.History of syphilis (Treponema pallidum). 8.Active hepatitis B or hepatitis C infection with confirmed antigen. 9.History of other malignancies within the past 5 years. 10.Presence of metastases with an expected lifespan of less than 1 year. 11.Concurrent participation, or participation within 3 months prior to the screening visit, in any other clinical trial that may interfere with the outcomes of this study. 12.Current or recent history of illicit drug or alcohol abuse or dependence. 13.Psychiatric or cognitive impairment that, in the investigator's judgment, compromises the patient's ability to comply with study requirements. 14.Any other condition that, in the investigator's opinion, renders the patient unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor Recurrence Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Progression-Free Survival;Safety Endpoints;Disease-Free Survival;Local Recurrence-Free Survival; | — |
Countries
China
Contacts
Public ContactZHOU YONG
West China Hospital of Sichuan University
Outcome results
None listed